The name was changed, following acquisition of Caris Diagnostics by Tokyo-based Miraca Holdings in November 2011.
Miraca Holdings provides clinical diagnostics and laboratory testing services.
Miraca Life Sciences chairman and CEO Takeo Hayashi said while the name has changed, the fundamental value proposition has not: a unique, high quality pathology practice with an abiding commitment to diagnostic excellence and improved patient care.